Growth failure and bony changes induced by deferoxamine.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  American Journal Of Pediatric Hematology/Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00043426-199221000-00007PMID 1550263
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical, biochemical and nutritional spectrum of zinc deficiency in human subjects: an update.

  2009cited by this paper
• Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major.

  1990cited by this paper
• Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage

  1989cited by this paper
• Transient partial growth hormone deficiency due to zinc deficiency.

  1989cited by this paper
• Deferoxamine-induced growth retardation in patients with thalassemia major.

  1988cited by this paper
• Effects of zinc supplementation on linear growth in beta‐thalassemia (A new approach)

  1987cited by this paper
• In vitro and in vivo effects of deferoxamine in neonatal acute leukemia.

  1987cited by this paper
• Leukocyte alkaline phosphatase (LAP). A useful marker of zinc status in beta-thalassemic patients.

  1987cited by this paper
• Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.

  1986cited by this paper
• Growth and sexual maturation in thalassemia major.

  1985cited by this paper
• Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

  1985cited by this paper
• Studies of marginal zinc deprivation in rhesus monkeys. V. Fetal and infant skeletal effects.

  1984cited by this paper
• Effects of low-zinc status and essential fatty acid deficiency on bone development and mineralization.

  1982cited by this paper
• Teratogenic aspects of manganese, zinc, and copper nutrition.

  1981cited by this paper
• Effect of zinc supplementation on serum testosterone level in adult male sickle cell anemia subjects

  1981cited by this paper
• Trace metals in mammalian development.

  1981cited by this paper
• The effect of zinc deficiency on alkaline phosphatase (EC 3.1.3.1) and its isoenzymes

  1980cited by this paper
• The radiographic manifestations of bone changes in copper deficiency

  1980cited by this paper
• Effect of zinc deficiency on bone collagenase and collagen turnover.

  1980cited by this paper
• Skeletal changes of copper deficiency in infants receiving prolonged total parenteral nutrition.

  1978cited by this paper
• Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.

  1976cited by this paper
• Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical Progress

  1974cited by this paper
• An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload

  1972cited by this paper
• Systemic bone disease developing in small premature infants.

  1971cited by this paper
• Role of copper in biosynthesis of intramolecular cross-links in chick tendon collagen.

  1969cited by this paper
• Cross-linking of collagen and elastin.

  1968cited by this paper
• Biochemical studies on dwarfism, hypogonadism, and anemia.

  1963cited by this paper
• Substituted naphthol AS phosphate derivatives for the localization of leukocyte alkaline phosphatase activity.

  1962cited by this paper
• Changes in the composition of the human femur during growth.

  1962cited by this paper
• Copper deficiency in infants; a syndrome characterized by hypocupremia, iron deficiency anemia, and hypoproteinemia.

  1956cited by this paper

• HEMATOLOGICAL AND BONE METABOLISM ABNORMALITIES IN CHILDREN AND ADOLESCENTS WITH Β-THALASSEMIA MAJOR

  2025cites this paper
• Targeted active surveillance of branded generic deferasirox in pediatric thalassemia patients in a tertiary care hospital of India: A pharmacovigilance study

  2025cites this paper
• Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies

  2024cites this paper
• Challenges of Iron Chelation in Thalassemic Children

  2024cites this paper
• Clinical Challenges with Iron Chelation in Beta Thalassemia.

  2023cites this paper
• Iron homeostasis in the heart: Molecular mechanisms and pharmacological implications.

  2022cites this paper
• Identification of osteopenia and osteoporotic changes in pediatric thalassemia patients at thalassemia center, Misan city, Iraq; An intervention study

  2022cites this paper
• The transfusion management of beta thalassemia in the United States

  2021cites this paper
• Skeletal radiological findings in thalassemia major

  2020cites this paper
• The Trabecular Bone Score as a Predictor for Thalassemia-Induced Vertebral Fractures in Northeastern Thailand

  2020cites this paper
• Hepatitis B and C Viral Infection in B-Thalassemic Children

  2019cites this paper
• Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran

  2019cites this paper
• Linking the low-density lipoprotein receptor-binding segment enables the therapeutic 5-YHEDA peptide to cross the blood-brain barrier and scavenge excess iron and radicals in the brain of senescent mice

  2019cites this paper
• Deferoxamine pretreatment inhibits metal neurotoxicity inCaenorhabditis elegans

  2019cites this paper
• Using the synthesized peptide HAYED (5) to protect the brain against iron catalyzed radical attack in a naturally senescence Kunming mouse model

  2019cites this paper
• Deferoxamine therapy for intracerebral hemorrhage: A systematic review

  2018cites this paper
• A contemporary therapeutic approach to bone disease in beta-thalassemia - a review

  2018cites this paper
• Comparison between Conventional Iron Chelating Medicine and Natural Iron Chelating Substance on Transfusion Dependent Thalassemia Patients - A Study from West Bengal, India

  2017cites this paper
• Iron overload in beta thalassemia major patients

  2017cites this paper
• Safety profiles of iron chelators in young patients with haemoglobinopathies

  2017cites this paper
• Iron overload in thalassemia: different organs at different rates.

  2017cites this paper
• Multifactorial Elements Affecting Bone Mineral Status and Growth in Children with Thalassemia Major

  2017cites this paper
• Хелаторная терапия у детей

  2016cites this paper
• Assessment and treatment of pain in thalassemia

  2016cites this paper
• Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease

  2016cites this paper
• Current growth patterns in children and adolescents with thalassemia major.

  2016cites this paper
• Clinical Manifestations , and Carrier Detection in

  2016cites this paper
• Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia

  2016cites this paper
• Distribution of BMI, Blood Groups, and Secretory Status Among Iraqi Patients with Beta Thalassemia Major

  2016cites this paper
• Hypoxia signalling manipulation for bone regeneration

  2015cites this paper
• Chapter 23 – Metal Antagonists

  2015cites this paper
• Iron Chelation in Thalassemia Major.

  2015cites this paper
• Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.

  2014cites this paper
• Thalassemia Bone Disease: A 19‐Year Longitudinal Analysis

  2014cites this paper
• Bone density in transfusion dependent thalassemia patients in Urmia, Iran

  2014cites this paper
• Original Article Bone density in transfusion dependent thalassemia patients in West Iran

  2014cites this paper
• Deferoxamine-induced dysplasia-like skeletal abnormalities at radiography and MRI

  2013influential citation
• Deferasirox: appraisal of safety and efficacy in long-term therapy

  2013cites this paper
• Evaluation and treatment of transfusional iron overload in children.

  2013cites this paper
• Management of the thalassemias.

  2013cites this paper
• Bone mineral density in beta thalassemia syndrome in Mosul city

  2013cites this paper
• Anemias and Bone Marrow Insufficiency

  2013cites this paper
• Optimal Use of Iron Chelators in Pediatric Patients

  2013cites this paper
• Current management of sickle cell anemia.

  2013cites this paper
• Thalassemia Major and Its Impact on Growth: Clinical Manifestations and Management of the Growing Thalassemic Child

  2012cites this paper
• Observational study comparing long‐term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation‐naïve children with transfusional iron overload

  2012cites this paper
• Overview of current chelation practices

  2012cites this paper
• Clinical Use of Iron Chelators

  2012cites this paper
• Adverse effects Local reactions Audiologic Ophthalmologic Allergic reactions Bone abnormalities Gastrointestinal Rash Rise in creatinine Elevated hepatic enzymes Gastrointestinal bleeding ¶ Gastrointestinal Neutropenia / agranulocytosis Arthralgia Elevated hepatic enzymes Pulmonary at high doses Neu

  2011cites this paper
• Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

  2011cites this paper
• Real-world use of iron chelators.

  2011cites this paper
• Bone disease and skeletal complications in patients with β thalassemia major.

  2011cites this paper
• Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.

  2010cites this paper
• Osteoporosis Syndrome in Thalassaemia Major: An Overview

  2010cites this paper
• Critical appraisal of growth retardation and pubertal disturbances in thalassemia

  2010cites this paper
• Hereditary Hemochromatosis and Iron Overload

  2010cites this paper
• Talasemi majorlu hastalarda kemik mineral yoğunluğu ile hipogonadizm arasındaki ilişki

  2010cites this paper
• New and Emerging Therapies for Osteoporosis

  2010cites this paper
• Mediterranean Journal of Hematology and Infectious Diseases Thalassaemia and Aberrations of Growth and Puberty

  2009cites this paper
• IRON OVERLOAD IN BETA THALASSEMIA - A Review

  2009cites this paper
• Chapter 15 – Imaging Findings of Drug-Related Musculoskeletal Disorders

  2009cites this paper
• Current status in iron chelation in hemoglobinopathies.

  2008cites this paper
• Review of radiologic skeletal changes in thalassemia.

  2008cites this paper
• BONE MINERAL DENSITY IN IRANIAN ADOLESCENTS AND YOUNG ADULTS WITH β-THALASSEMIA MAJOR

  2007cites this paper
• Normal lumbar bone mineral density in optimally treated children and young adolescents with beta-thalassaemia major.

  2007cites this paper
• Bone mineral density in Iranian adolescents and young adults with beta-thalassemia major.

  2007cites this paper
• Weekend Very High-dose Intravenous Deferoxamine in Children With Transfusional Iron Overload

  2006cites this paper
• Physiologie und Pathophysiologie des Eisenstoffwechsels

  2006cites this paper
• The radiological appearances of thalassaemia.

  2006cites this paper
• Growth of children with beta-thalassemia major.

  2005cites this paper
• Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients

  2005influential citation
• ENDOCRINE DISORDERS IN β-THALASSEMIA MAJOR: CROSS-SECTIONAL DATA

  2005cites this paper
• Desferrioxamine release from gelatin‐based systems

  2005cites this paper
• MRI marrow observations in thalassemia: The effects of the primary disease, transfusional therapy, and chelation

  2005cites this paper
• Linee guida per la ß-talassemia intermedia

  2005cites this paper
• MR imaging of deferoxamine-induced bone dysplasia in an 8-year-old female with thalassemia major

  2005influential citation
• Growth of children with β-thalassemia major

  2005cites this paper
• No Difference in Pubertal Growth and Final Height between Treated Hypogonadal and Non-Hypogonadal Thalassemic Patients

  2004cites this paper
• Radiographic and MRI features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia.

  2004cites this paper
• New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia

  2004cites this paper
• CLINICAL EVALUATION OF THE ORAL IRON CHELATOR DEFERIPRONE FOR THE POTENTIAL TREATMENT OF IRON OVERLOAD IN BIRD SPECIES

  2004cites this paper
• Endokrine Komplikationen bei Kindern mit ß-Thalassaemia major und intermedia

  2004influential citation
• Growth hormone secretion in polytransfused prepubertal patients with homozygous β-thalassemia. Effect of longterm recombinant GH (recGH) therapy

  2003cites this paper
• Endocrine Gland Abnormalities in Thalassemia Major: Λ Brief Review

  2003cites this paper
• Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with β‐thalassaemia disease

  2003cites this paper
• Neutrophil Apoptosis in Patients with β-Thalassemia Major

  2003cites this paper
• Neutrophil apoptosis in patients with beta-thalassemia major.

  2003cites this paper
• Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with beta-thalassaemia disease.

  2003cites this paper
• Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs

  2003cites this paper
• Design of iron chelators with therapeutic application

  2002cites this paper
• Design of clinically useful iron(III)‐selective chelators

  2002cites this paper
• Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia.

  2002cites this paper
• Imaging in Thalassaemia

  2002cites this paper
• Iron chelator chemistry.

  2002cites this paper
• Morbidity and mortality patterns of thalassaemia major patients in Hong Kong: retrospective study.

  2002cites this paper
• Results of long term iron chelation treatment with deferoxamine.

  2002cites this paper
• Liver disease in transfusion dependent thalassaemia major

  2002cites this paper
• Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia

  2002influential citation
• Endocrine complications of thalassemia

  2001cites this paper
• Liver iron estimation in beta-thalassaemia: comparison of MRI biochemical assay and histological grading.

  2001cites this paper